The discontinuation of STRIDES is a rare stumble for the next-generation obesity field and comes just weeks after Amgen ...
According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...
It is not clear what specifically the new facility will produce, though Amgen could be ramping up its manufacturing capacity ...
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...
Amgen AMGN announced the much-awaited 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy being developed for obesity and related conditions. The data showed that MariTide ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in those with diabetes after a year in a phase 2 trial. Despite higher ...
By Gina Kolata The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide ...
Amgen's MariTide challenges Lilly and Novo but falls short on efficacy and side effect profiles. Obesity market leaders Lilly and Novo strengthen dominance with advanced drugs nearing approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback